Annolyse
BriefingsCompaniesScreenerInsightsPrinciplesCompareChatWatchlist

Explore

  • Briefings
  • Companies
  • Screener
  • Insights
  • Compare

Resources

  • Search
  • Methodology

© 2026 Annolyse.

ChartsAnalysisChatData
  1. Charts
  2. Valuation
  3. Analysis
  4. Chat
  5. Data
  6. Sources
←Back to briefings
Iperion (IPR) / FY22

Headline 99.9% PBT improvement masks transition to NZ$2.0m shell

Total assets fell from NZ$2,154.5m to NZ$2.0m through an issuer transition, leaving zero revenue and only NZ$22k of cash.

Construction & Materials / Critical minerals

IPR revenue trajectory

Revenue context before the current result.

↗
Loading chart...
FY22 was $0m, versus $0.03m in FY21.

IPR operating cash flow

Operating cash flow across covered periods.

↗
Loading chart...
FY22 was -$0.12m, versus -$0.12m in FY21.

IPR NPAT trajectory

Statutory profit after tax across covered periods.

↗
Loading chart...
FY22 was -$0.2m, versus -$0.1m in FY21.

IPR ROE

Return on equity across covered periods.

↗
Loading chart...
FY22 was -8.7%, versus -5.7% in FY21.

Market context

Valuation

A close-dated read on what the market price implies next to the latest verified filing inputs. Unavailable metrics stay visible when the absence is useful context.

Prices as at close, 8 June 2026

Price and market cap

The latest close and share count context for the market price.

Market cap

$1.5m

i

End-of-day close multiplied by current shares on issue.

Profitability multiples

How the market price compares with recent earnings and cash-flow inputs.

P/E

Not available

i

Not meaningful when recent earnings are negative.

EPS

-0.00

i

Recent filing-derived earnings per share.

PEG

Not available

i

Not available for this company right now.

EV/EBITDA

Not available

i

Not meaningful when recent EBITDA is negative.

P/FCF

Not available

i

Not meaningful when free cash flow is negative or unavailable.

P/B

28.61x

i

Market value compared with latest reported equity.

Income and fund shape

Yield and fund-style valuation where the company shape supports it.

Dividend yield

0.0%

i

Trailing dividends compared with the latest close.

Total return

Not available

i

Available once dividend and adjustment data are verified.

Release date
30 May 2022
Published
23 April 2026
Ask about this result
Sections⌄
  1. Charts
  2. Valuation
  3. Analysis
  4. Chat
  5. Data
  6. Sources

Key metrics

Numbers worth scanning first

FY22 vs FY21

Revenue

$0m

Suppressed: metric quality flags mark this value as unsuitable for normal comparison.

Net profit after tax

−$0.2m

+99.8% ↑ vs −$117.6m

Net cash inflow from operating activities

−$0.12m

+99.9% ↑ vs −$123.6m

Profit before tax

−$0.2m

+99.8% ↑ vs −$117.6m

Cash and cash equivalents

$0.02m

Suppressed: metric quality flags mark this value as unsuitable for normal comparison.

Total assets

$2m

Suppressed: metric quality flags mark this value as unsuitable for normal comparison.

What changed

The most material event is an issuer transition that has reset the company to a listed shell

Total assets fell from NZ$2.2b to NZ$2.0m, equity from NZ$2.1b to NZ$1.9m, and cash from NZ$2.1b to NZ$0.022m. Revenue collapsed to zero from NZ$25.3m, which in the prior comparable was interest income on the legacy cash balance rather than operating revenue.

Against that backdrop, the headline PBT and NPAT both improved 99.9% to a NZ$0.2m loss from a NZ$117.6m loss, and operating cash outflow narrowed from NZ$123.6m to NZ$0.1m. These improvements are arithmetic consequences of the balance-sheet reset, not operating performance. The effective tax rate remained at 0.0% on both sides, so the PBT-to-NPAT read is clean but uninformative.

What matters

The 99.9% PBT improvement is scale mechanics, not an operating turnaround

  • Annolyse's historical baseline shows current total assets of NZ$2.0m sit within the company's normal shell-state range (NZ$0.5m–NZ$2.2b across the four-period window), with FY21 the outlier. This matters because the comparison flatters a company that no longer carries the cost base, capital, or revenue stream that produced the prior loss.
  • There is no operating business to analyse. Revenue is zero, cash is NZ$22k, and the cost base that generated the NZ$0.2m loss is what remains of corporate overhead. For an investor, this result describes a vehicle, not a business.
  • ROE moved from -5.7% to -8.7% on a collapsed equity base. This is "weakening" only in a technical sense — a tiny loss divided by a tiny equity number — and should not be read as deteriorating returns on a going concern.

Expectations

No targets or guidance were provided

The HY22 commentary stated the company "continues to look for appropriate acquisition targets with the support of the majority" shareholder, which is the only forward signal available. The current release does not update that stance, name a target, or quantify a funding plan.

With NZ$22k of cash and NZ$1.9m of equity, any meaningful acquisition would require fresh capital, scrip issuance, or vendor support. The result therefore supports nothing about a future business; it only confirms the shell remains intact and the search continues.

Quality of result

Durability is not the right lens here, because there is no recurring operating activity to assess

The reported NZ$0.2m loss is essentially residual corporate costs, and the narrower operating cash outflow simply reflects the absence of the prior period's wind-down distributions. Neither figure carries a read-through to a future operating margin, cash conversion, or working-capital cycle.

The cleaner takeaway is that the like-for-like comparison is not meaningful. FY21 financials describe an entity with NZ$2.15bn of assets and NZ$25.3m of interest income; FY22 describes a NZ$2.0m shell. Treating the 99.9% improvement as earnings progression would misread the filing. It is a presentational artefact of the issuer transition flagged in the supplied event overlay.

Unresolved

Open questions

What is the current acquisition pipeline, and on what timeline does the board expect a transaction?
How will any acquisition be funded given only NZ$22k of cash and NZ$1.9m of equity?
What annualised corporate cost base does the shell carry, and how long is the runway before further capital is required?
What drove the wind-down of the NZ$2.15bn legacy balance sheet during the period, and were proceeds returned to shareholders or transferred elsewhere?
Why is the listing being retained, and what is the majority shareholder's stated role in funding the next phase?

This briefing cannot assess the economics, valuation, or quality of any future acquired business, because none has been disclosed in the supplied release.

Chat

Ask about IPR FY22

Ask follow-up questions about Iperion's FY22 result.

Informational only. No buy, sell, hold, price-target, or personal financial advice.

Ask about IPR FY22

Informational only. No buy, sell, hold, price-target, or personal financial advice.

Sign in to chat

Sign in to ask questions about Iperion's FY22 result.

What is the current acquisition pipeline, and on what timeline does the board expect a transaction?Why does "The 99.9% PBT improvement is scale mechanics, not an operating turnaround" matter?How strong was the cash and earnings quality in FY22?What should I watch next for IPR after FY22?

Checking account...

Data appendix

Show analytical metrics

Open to load analytical metrics.

Show key metrics table

Open to load key metrics.

Sources

Current period

SNC Preliminary Full Year Result 2022

FY22 / financial report↗

Prior comparable period

SNC Preliminary Full Year Result 2021

FY21 / financial report↗

Interim context

SNC 1H22 Interim Report

HY22 / financial report↗

SNC 1H22 NZX Results Template

HY22 / results announcement↗

Related insights

Cross-company views selected from the metrics in this briefing.

Earnings quality and statutory distortions

PBT and NPAT growth diverged by 0.0pp.

→

ROE and capital efficiency

ROE was -8.7%, -3.0pp versus the prior comparable period.

→
This briefing is based on available company filings and standard Annolyse calculations. It is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.

Get notified when IPR publishes next

Get the next Iperion briefing and related NZX reporting-season updates by email.